Published in J Cereb Blood Flow Metab on March 27, 2013
Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime cognitive and brain phenotyping to the level of the synapse. Acta Neuropathol Commun (2015) 1.39
Post-mortem assessment in vascular dementia: advances and aspirations. BMC Med (2016) 0.98
Pathophysiology of white matter perfusion in Alzheimer's disease and vascular dementia. Brain (2014) 0.87
Cerebrovascular disease in ageing and Alzheimer's disease. Acta Neuropathol (2015) 0.87
Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes. Front Aging Neurosci (2014) 0.84
Frontal white matter hyperintensities, clasmatodendrosis and gliovascular abnormalities in ageing and post-stroke dementia. Brain (2015) 0.83
Pathophysiology of Hypoperfusion of the Precuneus in Early Alzheimer's Disease. Brain Pathol (2015) 0.79
Synaptic protein levels altered in vascular dementia. Neuropathol Appl Neurobiol (2015) 0.78
Chronic Cerebral Ischemia Induces Downregulation of A1 Adenosine Receptors During White Matter Damage in Adult Mice. Cell Mol Neurobiol (2015) 0.77
Gender differences in white matter pathology and mitochondrial dysfunction in Alzheimer's disease with cerebrovascular disease. Mol Brain (2016) 0.76
Protective effects of carnosine on white matter damage induced by chronic cerebral hypoperfusion. Neural Regen Res (2016) 0.75
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology (1991) 23.01
Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging (1997) 10.81
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol (2000) 9.73
15-year longitudinal study of blood pressure and dementia. Lancet (1996) 6.44
Midlife cardiovascular risk factors and risk of dementia in late life. Neurology (2005) 5.12
Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology (2005) 4.04
Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology (2006) 3.68
White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke (2006) 3.27
Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology (1996) 3.23
Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A (2006) 2.66
The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging (2000) 2.30
Myelin-associated glycoprotein demonstrated immunocytochemically in myelin and myelin-forming cells of developing rat. Proc Natl Acad Sci U S A (1979) 1.97
Cortical microinfarcts and demyelination significantly affect cognition in brain aging. Stroke (2004) 1.74
Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol (2002) 1.70
Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci U S A (2000) 1.66
The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology (1996) 1.64
Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol (2003) 1.55
APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. Neuropathol Appl Neurobiol (2003) 1.53
The myelin-associated glycoprotein is enriched in multivesicular bodies and periaxonal membranes of actively myelinating oligodendrocytes. J Cell Biol (1989) 1.52
A beta-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol (2001) 1.26
Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. Ann Neurol (1985) 1.25
Immunocytochemical observations on the distribution of myelin-associated glycoprotein and myelin basic protein in multiple sclerosis lesions. Ann Neurol (1980) 1.23
Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. Arch Neurol (1995) 1.22
Cardiovascular and other risk factors for Alzheimer's disease and vascular dementia. Ann N Y Acad Sci (2000) 1.21
Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP. Neurobiol Aging (2007) 1.21
Immunocytochemical localization of basic protein in major dense line regions of central and peripheral myelin. J Cell Biol (1982) 1.20
Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res (2009) 1.15
Cerebral beta amyloid angiopathy is a risk factor for cerebral ischemic infarction. A case control study in human brain biopsies. J Neuropathol Exp Neurol (2000) 1.11
The initial events in myelin synthesis: orientation of proteolipid protein in the plasma membrane of cultured oligodendrocytes. J Cell Biol (1989) 1.02
Cerebral subcortical small vessel disease and its relation to cognition in elderly subjects: a pathological study in the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort. Neuropathol Appl Neurobiol (2012) 1.00
Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid-β. J Alzheimers Dis (2012) 0.98
Evidence for a "dying-back" gliopathy in demyelinating disease. Ann Neurol (1981) 0.90
Effect of hypoxia/ischemia and hypoxic preconditioning/reperfusion on expression of some amyloid-degrading enzymes. Ann N Y Acad Sci (2004) 0.86
Contribution of cerebral amyloid angiopathy to Alzheimer's disease. J Neurol Neurosurg Psychiatry (2004) 0.83
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet (2008) 8.51
Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol (2007) 5.27
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol (2008) 2.26
Thalamic neurodegeneration in multiple sclerosis. Ann Neurol (2002) 2.20
Diffusion imaging of whole, post-mortem human brains on a clinical MRI scanner. Neuroimage (2011) 1.88
Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain (2005) 1.87
Estimated neuronal populations and volumes of the hippocampus and its subfields in schizophrenia. Am J Psychiatry (2002) 1.74
Axonal injury in cerebral malaria. Am J Pathol (2002) 1.65
Asymmetry of the uncinate fasciculus: a post-mortem study of normal subjects and patients with schizophrenia. Cereb Cortex (2002) 1.53
Sequestration and microvascular congestion are associated with coma in human cerebral malaria. J Infect Dis (2011) 1.52
Amygdala volume in schizophrenia: post-mortem study and review of magnetic resonance imaging findings. Br J Psychiatry (2002) 1.52
T cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides. Immunity (2009) 1.50
Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med (2005) 1.49
Haplotype-specific expression of exon 10 at the human MAPT locus. Hum Mol Genet (2006) 1.47
Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol (2011) 1.42
Absence of detection of varicella-zoster virus DNA in temporal artery biopsies obtained from patients with giant cell arteritis. J Neurol Sci (2003) 1.42
Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain (2005) 1.33
TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol (2011) 1.32
Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol (2006) 1.31
Angiotensins in Alzheimer's disease - friend or foe? Trends Neurosci (2009) 1.25
A preliminary neuropathological study of Japanese encephalitis in humans and a mouse model. Trans R Soc Trop Med Hyg (2006) 1.23
A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. Brain (2012) 1.22
Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol (2009) 1.16
Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res (2009) 1.15
Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol (2007) 1.15
Ischemic stroke in the elderly: an overview of evidence. Nat Rev Neurol (2010) 1.15
Spinal cord gray matter demyelination in multiple sclerosis-a novel pattern of residual plaque morphology. Brain Pathol (2006) 1.13
Distribution and expression of picalm in Alzheimer disease. J Neuropathol Exp Neurol (2010) 1.13
Genome wide profiling of altered gene expression in the neocortex of Alzheimer's disease. J Neurosci Res (2010) 1.13
Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry (2002) 1.12
IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. Am J Pathol (2011) 1.11
Epilepsy surgery for refractory epilepsy due to encephalocele: a case report and review of the literature. Epileptic Disord (2010) 1.09
Alpha-synuclein pathology in the olfactory pathways of dementia patients. J Anat (2007) 1.08
Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol (2006) 1.07
The pathogenesis of neonatal post-hemorrhagic hydrocephalus. Brain Pathol (2004) 1.06
Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. Hum Mutat (2004) 1.06
Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J Neuropathol Exp Neurol (2009) 1.05
Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta. Am J Pathol (2009) 1.05
Measurement of pre- and post-synaptic proteins in cerebral cortex: effects of post-mortem delay. J Neurosci Methods (2004) 1.04
Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. Brain Pathol (2010) 1.03
Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. Brain (2013) 1.03
The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis (2012) 1.02
Spinal cord neuronal pathology in multiple sclerosis. Brain Pathol (2008) 1.01
Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol (2010) 1.01
Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease. Neurochem Res (2009) 1.00
Unilateral subthalamotomy in the treatment of Parkinson's disease. Brain (2003) 1.00
Memory loss resulting from fornix and septal damage: impaired supra-span recall but preserved recognition over a 24-hour delay. Neuropsychology (2008) 0.99
Anomalies of asymmetry of pyramidal cell density and structure in dorsolateral prefrontal cortex in schizophrenia. Br J Psychiatry (2006) 0.99
Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain. Neurobiol Aging (2005) 0.99
Spinal cord atrophy in multiple sclerosis caused by white matter volume loss. Arch Neurol (2005) 0.98
Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci Lett (2008) 0.98
Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid-β. J Alzheimers Dis (2012) 0.98
Characterisation of two antibodies to oligomeric Abeta and their use in ELISAs on human brain tissue homogenates. J Neurosci Methods (2008) 0.97
CNS SIRT3 expression is altered by reactive oxygen species and in Alzheimer's disease. PLoS One (2012) 0.96
Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain (2005) 0.95
Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res (2003) 0.94
Distribution of the branched chain aminotransferase proteins in the human brain and their role in glutamate regulation. J Neurochem (2012) 0.93
Novel deletion of lysine 7 expands the clinical, histopathological and genetic spectrum of TPM2-related myopathies. Brain (2013) 0.93
Higher soluble amyloid beta concentration in frontal cortex of young adults than in normal elderly or Alzheimer's disease. Brain Pathol (2010) 0.93
Oligomeric Abeta in Alzheimer's disease: relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy. Brain Pathol (2009) 0.92
ACE variants and association with brain Aβ levels in Alzheimer's disease. Am J Transl Res (2010) 0.91
No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2011) 0.91
Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimer's disease neuropathology. J Neural Transm (Vienna) (2008) 0.91
Microanatomical correlates of cognitive ability and decline: normal ageing, MCI, and Alzheimer's disease. Cereb Cortex (2011) 0.91
Posthemorrhagic ventricular dilation in the neonate: development and characterization of a rat model. J Neuropathol Exp Neurol (2003) 0.91
The neuropathology of vascular disease in the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Curr Alzheimer Res (2012) 0.91
Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia. BMC Neurol (2007) 0.90
Minicolumn thinning in temporal lobe association cortex but not primary auditory cortex in normal human ageing. Acta Neuropathol (2006) 0.89
Diffuse cortical atrophy in a marmoset model of multiple sclerosis. Neurosci Lett (2008) 0.89
A multi-center study of ACE and the risk of late-onset Alzheimer's disease. J Alzheimers Dis (2011) 0.89
Kallikrein-related peptidase 6 in Alzheimer's disease and vascular dementia. Brain Res (2010) 0.89
Accumulation of insoluble amyloid-β in down's syndrome is associated with increased BACE-1 and neprilysin activities. J Alzheimers Dis (2011) 0.89
Neprilysin protects against cerebral amyloid angiopathy and Aβ-induced degeneration of cerebrovascular smooth muscle cells. Brain Pathol (2011) 0.88
Concurrent multiple sclerosis and amyotrophic lateral sclerosis: where inflammation and neurodegeneration meet? J Neuroinflammation (2012) 0.88
Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations. Brain Pathol (2013) 0.87
Neurofibrillary tangles may interfere with Smad 2/3 signaling in neurons. J Neuropathol Exp Neurol (2007) 0.87
Loss of perineuronal net N-acetylgalactosamine in Alzheimer's disease. Acta Neuropathol (2005) 0.87
Pathophysiology of white matter perfusion in Alzheimer's disease and vascular dementia. Brain (2014) 0.87
Macroscopic brain asymmetry is changed along the antero-posterior axis in schizophrenia. Schizophr Res (2005) 0.87
Clusterin mRNA and protein in Alzheimer's disease. J Alzheimers Dis (2012) 0.87
Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. J Neurosci Methods (2007) 0.87
Convection-enhanced delivery of neprilysin: a novel amyloid-β-degrading therapeutic strategy. J Alzheimers Dis (2012) 0.86
Late-onset hereditary sensory neuropathy type I due to SPTLC1 mutation: autopsy findings. Clin Neurol Neurosurg (2005) 0.86
Brain burdens of aluminum, iron, and copper and their relationships with amyloid-β pathology in 60 human brains. J Alzheimers Dis (2012) 0.86
Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiol Aging (2005) 0.86
Aβ immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy. Acta Neuropathol (2014) 0.85
Endothelin receptor antagonists: potential in Alzheimer's disease. Pharmacol Res (2010) 0.85
Association between subcortical vascular disease on CT and neuropathological findings. Int J Geriatr Psychiatry (2004) 0.85
Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions. J Neuroimmunol (2012) 0.85
Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival. Am J Surg Pathol (2002) 0.84
Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. Neurobiol Dis (2006) 0.84
Endothelin-converting enzyme-1 activity, endothelin-1 production, and free radical-dependent vasoconstriction in Alzheimer's disease. J Alzheimers Dis (2013) 0.84
Accumulation of cortical hyperphosphorylated neurofilaments as a marker of neurodegeneration in multiple sclerosis. Mult Scler (2012) 0.84
TNFR-associated factor-2 (TRAF-2) in Alzheimer's disease. Neurobiol Aging (2007) 0.84